$8.58
-0.27 (-3.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ACOG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · insider 90d: 12 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)NCT07633470Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 4 | Recruiting | Drug: Zunveyl® | Alzheimer Disease | 150 | Apr 2027 | ≤ 254 d | 2026-07-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19